美国心脏协会更新:草绿色链球菌感染性心内膜炎预防建议
美国心脏协会联合多个学会组成写作组,系统检索MEDLINE后评估2007年草绿色链球菌心内膜炎预防指南的依从性与影响,发现总体知晓率高但依从性不一,且无证据表明草绿色链球菌心内膜炎频率、发病率或死亡率上升,故不建议修改2007年指南,仍仅推荐最高危患者预防。
要点
- 不修改2007年指南,仍仅对最高危心脏患者推荐草绿色链球菌心内膜炎预防。
- 强调所有患者保持良好口腔健康和定期牙科照护的关键作用。
- 现有证据未显示2007年后草绿色链球菌心内膜炎频率、发病率或死亡率增加。
核心结论
- 基于现有证据,不建议修改2007年草绿色链球菌感染性心内膜炎预防指南。
- 仍仅推荐最高危不良结局患者接受草绿色链球菌心内膜炎预防,并强调所有患者保持良好口腔健康和定期牙科照护。
- 需要随机对照研究确定抗生素预防对草绿色链球菌心内膜炎是否有效,以进一步细化建议。
研究设计与样本
- 美国心脏协会联合美国牙科协会、美国感染病学会、美国儿科学会等组成写作组,检索MEDLINE英文文献,评估2007年指南的依从性及草绿色链球菌心内膜炎的频率、发病率或死亡率。
主要发现
- 对2007年指南总体知晓良好,但依从性不一。
- 无令人信服的证据表明2007年后草绿色链球菌心内膜炎频率、发病率或死亡率增加。
临床怎么用
- 口腔科医生应知晓2007年指南仅对最高危心脏患者推荐草绿色链球菌心内膜炎预防。
- 应强调所有患者保持良好口腔健康和定期牙科照护的关键作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2007, the American Heart Association published updated evidence-based guidelines on the recommended use of antibiotic prophylaxis to prevent viridans group streptococcal (VGS) infective endocarditis (IE) in cardiac patients undergoing invasive procedures. The 2007 guidelines significantly scaled back the underlying conditions for which antibiotic prophylaxis was recommended, leaving only 4 categories thought to confer the highest risk of adverse outcome. The purpose of this update is to examine interval evidence of the acceptance and impact of the 2007 recommendations on VGS IE and, if needed, to make revisions based on this evidence. METHODS AND RESULTS: A writing group was formed consisting of experts in prevention and treatment of infective endocarditis including members of the American Dental Association, the Infectious Diseases Society of America, and the American Academy of Pediatrics, in addition to the American Heart Association. MEDLINE database searches were done for English language articles on compliance with the recommendations in the 2007 guidelines and the frequency of and morbidity or mortality from VGS IE after publication of the 2007 guidelines. Overall, there was good general awareness of the 2007 guidelines but variable compliance with recommendations. There was no convincing evidence that VGS IE frequency, morbidity, or mortality has increased since 2007. CONCLUSIONS: On the basis of a review of the available evidence, there are no recommended changes to the 2007 VGS IE prevention guidelines. We continue to recommend VGS IE prophylaxis only for categories of patients at highest risk for adverse outcome while emphasizing the critical role of good oral health and regular access to dental care for all. Randomized controlled studies to determine whether antibiotic prophylaxis is effective against VGS IE are needed to further refine recommendations.
引用
- Wilson WR, Gewitz M, Lockhart PB, et al. Adapted from: Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association. J Am Dent Assoc. 2021. PMID: 34711348. doi:10.1016/j.adaj.2021.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。